Journals / Kocaeli Tıp Dergisi / 2019 / Cilt: 8 - Sayı: 1

Comparison of The Outcomes of rFSH Alone Versus rFSH + rLH Protocols in Patients Undergoing Controlled Ovarian Hyperstimulation for IVF Cycles

IVF Sikluslarında Kontrollü Ovaryen Hiperstimulasyonu Uygulanan Hastalarda Yalnız rFSH ile rFSH + rLH Kombinasyon Protokolleri Sonuçlarının Karşılaştırılması

Pages
195–201
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It should be considered however, to provethe efficacy, larger scale prospective randomized control trials shouldbe conducted.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:INTRODUCTION: Gonadotropin therapy is the mainstay of ovarian stimulation, while FSH is the main regulator of antral follicular growth, LH plays key roles in promoting steroidogenesis and in the development of the leading follicle.
📊
Key Findings & Data:The aim of this prospective randomized study is to investigate the efficacy of the administration of rLH during COH in normogonadotrophic downregulated women, with initial normal - suboptimal ovarian response to monotherapy with rFSH.METHODS: Seventy seven patients were included in the study andtwo regimens, rFSH and rFSH + rLH, for IVF treatment of women with normal and decreased ovarian function were compared in prospective randomised fashion.
💡
Conclusion & Impact:It should be considered however, to provethe efficacy, larger scale prospective randomized control trials shouldbe conducted.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

INTRODUCTION: Gonadotropin therapy is the mainstay of ovarian stimulation, while FSH is the main regulator of antral follicular growth, LH plays key roles in promoting steroidogenesis and in the development of the leading follicle. However, there is limited data on the use of LH supplementation in controlled ovarian stimulation for IVF. The aim of this prospective randomized study is to investigate the efficacy of the administration of rLH during COH in normogonadotrophic downregulated women, with initial normal - suboptimal ovarian response to monotherapy with rFSH.METHODS: Seventy seven patients were included in the study andtwo regimens, rFSH and rFSH + rLH, for IVF treatment of women with normal and decreased ovarian function were compared in prospective randomised fashion. Primary end-point of the study was the total number of metaphase II oocytes.RESULTS: Of the 77 patients, 39 received FSH alone (Group A) and38 received FSH + LH (Group B). When all age groups were evaluated,number of metaphase II oocytes and total embryos were statisticallysignificantly decreased in group B compared to groups A (p< 0.01).Particularly, in the subgroup of patients aged 35 years and over, number of metaphase II oocytes were statistically significantly decreased in group B compared to group A (p< 0.005). The number ofgood quality embryos and clinical pregnancy rates did not differsignificantly between the two groups either in all age groups andpatients aged ≥35.DISCUSSION and CONCLUSION: rFSH+rLH regimen appears notto be beneficial for the IVF treatment of women either with normal anddecreased ovarian reserve. It should be considered however, to provethe efficacy, larger scale prospective randomized control trials shouldbe conducted.

Özet

GİRİŞ ve AMAÇ: Gonadotropin tedavisi, overyan stimülasyonun temelidir. FSH, antral folliküler büyümenin ana düzenleyicisi iken, LH ise steroidogenezin desteklenmesi ve antral follikül gelişiminde önemli rol oynar. Bununla birlikte, literatürde LH desteğinin, kontrollü ovaryan hiperstimülasyonuna eklenmesi hakkında sınırlı veri bulunmaktadır. Prospektif randomize çalışmamızın amacı, hipofizi baskılanmış normo-gonadotropik ve rFSH ile monoterapiye normal - suboptimal over cevabı olan kadınlarda kontrollü ovaryan hiperstimülasyon sırasında tedaviye rLH eklenmesinin etkinliğini araştırmaktır. YÖNTEM ve GEREÇLER: Çalışmaya yetmiş yedi hasta dahil edildi. IVF tedavisine alınan normal ve azalmış over fonksiyonuna sahip hastalar randomize edildi ve kontrollü overyan hiperstimülasyon esnasında, rFSH ile rFSH + rLH rejimleri prospektif olarak karşılaştırıldı. Çalışmanın birincil sonlanım noktası, toplam metafaz II oosit sayısı olarak kabul edildi. BULGULAR: Çalışmaya dahil olan yetmiş yedi hastadan otuz dokuzu, yalnız FSH (Grup A) ve otuz sekizi de FSH + LH (Grup B) aldı. Tüm yaş grupları içinde değerlendirildiğinde, grup B'de elde edilen metafaz II oosit ve toplam embriyo sayıları grup A'ya göre istatistiksel olarak anlamlı derecede azdı. Otuz beş yaş ve üstü hastalar ayrıca değerlendirildiğinde, metafaz II oosit sayısı, rFSH + rLH alan grupta istatistiksel olarak anlamlı derecede azalmış olarak saptandı. Hem tüm yaş gruplarındaki hastalar, hem de otuz beş yaş ve üstü hastalar değerlendirildiğinde iyi kalitede embriyo sayısı ve klinik gebelik oranları bakımından, her iki grup arasında istatistiksel olarak anlamlı farklılık izlenmedi. TARTIŞMA ve SONUÇ: Çalışmamızda, IVF tedavisinde rFSH + rLH rejiminin, hem normal hem de azalmış over rezervi olan kadınlarda faydalı olmadığı görülmektedir. Bununla birlikte, hasta sayısının daha fazla olduğu prospektif randomize kontrollü çalışmalarının yapılması gerektiğini düşünmekteyiz.

🔖

Cite This Article

MİNARECİ, Y., ÖZCAN, U. (2022). Comparison of The Outcomes of rFSH Alone Versus rFSH + rLH Protocols in Patients Undergoing Controlled Ovarian Hyperstimulation for IVF Cycles. Kocaeli Tıp Dergisi, Cilt: 8 - Sayı: 1, 195–201. https://ajindex.com/articles/574827

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Mennini FS, Marcellusi A, Viti R, Bini C, Carosso A, Revelli A, et al. Probabilistic costeffectiveness analysis of controlled ovarian stimulation with recombinant FSHplus recombinant LH vs. human menopausal gonadotropin for women undergoing IVF. Reprod Biol Endocrinol. 2018 Jul 18;16(1):68
  2. Leao RdB, Esteves SC. Gonadotropin therapy in assisted reproduction: an evolutionary perspective from biologics to biotech. Clinics (Sao Paulo) 2014;69:279– 93
  3. Alviggi C, Conforti A, Esteves SC, Andersen CY, Bosch E, Bühler K. Recombinant luteinizing hormone supplementation in assisted reproductive technology: a systematic review. Fertil Steril. 2018 Apr;109(4):644-64
  4. Seibel MM. Oocyte maturation and follicle development In:. Seibel MM, (eds), Appleton & Lange, Norwalk, 37, 1990. Chapter 8, Infertility; p 124-67
  5. Filicori M, Cognigni GE, Pocognoli P, Ciampaglia W, Bernardi S. Current conceptsand novel applications of LH activity in ovarian stimulation. Trends Endocrinol Metab 2003;14:267–73
  6. Alviggi C, Clarizia R, Mollo A, Ranieri A, de Placido G. Outlook: who needsLH in ovarian stimulation? Reprod Biomed Online 2006;12:599–607
  7. Yding Andersen C. Inhibin-B secretion and FSH isoform distribution may play an integral part of follicular selection in the natural menstrual cycle. Mol Hum Reprod 2016;23:16–24
  8. Acevedo B, Sanchez M, Gomez JL, Cuadros J, Ricciarelli E, Hernández ER, et al. Luteinizing hormone supplementation increases pregnancy rates in gonadotropinreleasinghormone antagonist donor cycles. Fertil Steril. 2004 Aug;82(2):343-7
  9. De Placido G, Alviggi C, Mollo A, Strina I, Ranieri A, Alviggi E, et al. Effects of recombinant LH (rLH) supplementation during controlled ovarian hyperstimulation (COH) in normogonadotrophic women with an initial inadequate response to recombinant FSH(rFSH) after pituitary downregulation. Clin Endocrinol (Oxf). 2004 May;60(5):637- 43
  10. Recombinant Human LH Study Group. Recombinant human luteinizing hormone (LH) to support recombinant human folliclestimulating hormone (FSH)-induced follicular development in LHand FSHdeficient anovulatory women: a dose-finding study. J Clin Endocrinol Metab 1998;83:1507–14
  11. Fleming R, Lloyd F, Herbert M, et al. Effects of profound suppression of luteinizing hormone during ovarian stimulation on follicular activity, oocyte and embryo function in cycles stimulated with purified follicle stimulating hormone. Hum Reprod 1998;13:1788–92
  12. Filicori M, Cognigni GE, Taraborrel